Christian Rolfo
Christian Rolfo
Professor in Oncology, Head of Phase I -Early Clinical Trials Unit, Oncology, Antwerp University
Verified email at
Cited by
Cited by
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre …
R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ...
The lancet oncology 13 (3), 239-246, 2012
Screening for epidermal growth factor receptor mutations in lung cancer
R Rosell, T Moran, C Queralt, R Porta, F Cardenal, C Camps, M Majem, ...
New England Journal of Medicine 361 (10), 958-967, 2009
Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC
C Rolfo, PC Mack, GV Scagliotti, P Baas, F Barlesi, TG Bivona, RS Herbst, ...
Journal of thoracic oncology 13 (9), 1248-1268, 2018
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
U Banerji, CML van Herpen, C Saura, F Thistlethwaite, S Lord, V Moreno, ...
The Lancet Oncology 20 (8), 1124-1135, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
A Drilon, S Siena, R Dziadziuszko, F Barlesi, MG Krebs, AT Shaw, ...
The Lancet Oncology 21 (2), 261-270, 2020
Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer
C Rolfo, P Mack, GV Scagliotti, C Aggarwal, ME Arcila, F Barlesi, T Bivona, ...
Journal of Thoracic Oncology 16 (10), 1647-1662, 2021
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
M Román, I Baraibar, I López, E Nadal, C Rolfo, S Vicent, I Gil-Bazo
Molecular cancer 17, 1-14, 2018
Impact of the COVID-19 pandemic on cancer care: a global collaborative study
AR Jazieh, H Akbulut, G Curigliano, A Rogado, AA Alsharm, ED Razis, ...
JCO global oncology 6, 1428-1438, 2020
The role of nuclear factor-kappa B signaling in human cervical cancer
S Tilborghs, J Corthouts, Y Verhoeven, D Arias, C Rolfo, XB Trinh, ...
Critical reviews in oncology/hematology 120, 141-150, 2017
FGFR a promising druggable target in cancer: Molecular biology and new drugs
R Porta, R Borea, A Coelho, S Khan, A Araújo, P Reclusa, T Franchina, ...
Critical reviews in oncology/hematology 113, 256-267, 2017
A comparison of cell-free DNA isolation kits: isolation and quantification of cell-free DNA in plasma
L Sorber, K Zwaenepoel, V Deschoolmeester, G Roeyen, F Lardon, ...
The journal of molecular diagnostics 19 (1), 162-168, 2017
Liquid biopsies in lung cancer: the new ambrosia of researchers
C Rolfo, M Castiglia, D Hong, R Alessandro, I Mertens, G Baggerman, ...
Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1846 (2), 539-546, 2014
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies
N Boeckx, R Koukakis, KO De Beeck, C Rolfo, G Van Camp, S Siena, ...
Annals of Oncology 28 (8), 1862-1868, 2017
RET fusions in solid tumors
AY Li, MG McCusker, A Russo, KA Scilla, A Gittens, K Arensmeyer, ...
Cancer treatment reviews 81, 101911, 2019
CD70: An emerging target in cancer immunotherapy
J Jacobs, V Deschoolmeester, K Zwaenepoel, C Rolfo, K Silence, ...
Pharmacology & therapeutics 155, 1-10, 2015
Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer
U Malapelle, R Sirera, E Jantus-Lewintre, P Reclusa, S Calabuig-Fariñas, ...
Expert review of molecular diagnostics 17 (3), 209-215, 2017
Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients
L Sorber, K Zwaenepoel, V Deschoolmeester, PEY Van Schil, ...
Lung cancer 107, 100-107, 2017
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
A Leonetti, B Wever, G Mazzaschi, YG Assaraf, C Rolfo, F Quaini, M Tiseo, ...
Drug Resistance Updates 46, 100644, 2019
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
F Passiglia, G Bronte, V Bazan, C Natoli, S Rizzo, A Galvano, A Listì, ...
Oncotarget 7 (15), 19738, 2016
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
VSS Bradley CA, Salto-Tellez M, Laurent-Puig P, Bardelli A, Rolfo C ...
Nat Rev Clin Oncol, 2017
The system can't perform the operation now. Try again later.
Articles 1–20